BMS-986010 is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin 23 (IL-23). It reduces IL-23-induced STAT3 phosphorylation, inhibits Th17 cell differentiation, and suppresses the release of pro-inflammatory cytokines such as IL-17 and TNF-alpha. BMS-986010 shows promise in research on autoimmune diseases, including psoriasis and Crohns disease.
Target:
Interleukin
* VAT and and shipping costs not included. Errors and price changes excepted
